

<HTML>
<HEAD>

<link rel="stylesheet" href="/v3.css" type="text/css">










<TITLE>NEJM -- Case 34-2003 - A 45-Year-Old Woman with a Family History of Colonic Polyps and Cancer</TITLE>
<meta name="description" content="Case Records of the Massachusetts General Hospital from The New England Journal of Medicine -- Case 34-2003 - A 45-Year-Old Woman with a Family History of Colonic Polyps and Cancer">

<meta name="robots" content="nofollow">




<script type="text/javascript" src="/misc/folders.js"></script>
</HEAD>


  

























	




















<!-- start PPT check-->


<!-- end PPT check-->









 
 
  







<body bgcolor="#FFFFFF" link="#FF3300" vlink="#666699" text="#000000" alink="#FF3300">

<!-- BEGIN: Use this section to set page specific variables for the NetTracker Page Tag -->
<script language="JavaScript">
// var NTPT_PGEXTRA = '';
// var NTPT_PGREFTOP = false;
// var NTPT_NOINITIALTAG = false;
</script>
<!-- END: Use this section to set page specific variables for the NetTracker Page Tag -->
<!-- BEGIN: NetTracker Page Tag -->
<!-- Copyright 2004 Sane Solutions, LLC. All rights reserved. -->
<script language="JavaScript" src="/ntpagetag.js"></script>
<noscript>
<img src="/icons/ntpagetag.gif?js=0" height="1" width="1" border="0" hspace="0" vspace="0" alt="">
</noscript>
<!-- END: NetTracker Page Tag -->







<!-- No CheckM8 category -->




<A NAME="top"><!-- null --></A>

	<table width="100%" border="0" cellspacing="0" cellpadding="0" align="center">
	
	
	<tr align="center"> 
	<td bgcolor="#FF3300"><img src="/icons/spacer.gif" width="1" height="3" alt=""></td>
	</tr>
	
	<tr align="center"> 
	<td><a href="/"><img src="/icons/banner/v2_title_large.gif" border="0" alt="The New England Journal of Medicine" width="482" height="95"></a></td>
	</tr>
	
	<tr> 
	<td valign="top" align="center" bgcolor="#E8E8D1"><img src="/icons/spacer.gif" width="100%" height="5" alt=""></td>
	</tr>
	
	<tr> 
	<td valign="top" align="center" bgcolor="#E8E8D1"><font face="arial, helvetica, sans-serif">
<a href="/" class="navBarLinks">HOME</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/search.dtl" class="navBarLinks">SEARCH</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/current.shtml" class="navBarLinks">CURRENT ISSUE</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/contents-by-date.0.shtml" class="navBarLinks">PAST ISSUES</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/collections/" class="navBarLinks">COLLECTIONS</a>
&nbsp;&nbsp;|&nbsp;&nbsp; <a href="/help/" class="navBarLinks">HELP</a>
</font></td>
	</tr>
	
	<tr> 
	<td valign="top" align="center" bgcolor="#E8E8D1"><img src="/icons/spacer.gif" width="100%" height="5" alt=""></td>
	</tr>
	
	<tr> 
	<td valign="top" align="center" bgcolor="#FF3300"><img src="/icons/spacer.gif" width="1" height="3" alt=""></td>
	</tr>
	
	<tr> 
	<td><img src="/icons/spacer.gif" width="100%" height="1" alt=""></td>
	</tr>
	
	<tr> 
	<td><font face="arial, helvetica, sans-serif" size="-2"><!-- subline logic: standard default -->







	
	

	





	
	
	
	 

	


	
	




				<FONT SIZE=-2>




				<NOBR><STRONG>Institution: BRANDEIS UNIV</STRONG></NOBR>

				
	   				
					
				
				| <NOBR><A TARGET="_top" HREF="/cgi/login?uri=%2Fcgi%2Fcontent%2Ffull%2F349%2F18%2F1750">Sign In as Individual</A></NOBR>
				|
				<NOBR><A TARGET="_top" HREF="mailto:keen@brandeis.edu">Contact Subscription Administrator at Your Institution</A></NOBR>
				
				 | <NOBR><STRONG><A TARGET="_top" HREF="http://www.nejm.org/Institute/faq.asp">FAQ</A></STRONG></NOBR>

				</FONT>
			

 <!-- showauthstring -->
	<!-- INST -->
	<!-- INDV -->
        <!-- SPONSORED -->
	<!-- USER.PFA -->
	<!-- USER.PFABSAIC -->
	<!-- NOT GUEST -->
	

	


</font></td>
	</tr>
	
		
		<tr>
		<td>&nbsp;</td>
		</tr>
	
	
	</table>
	
	
<!-- include file -->
<!-- (do not remove) -->




         
                
        






<CENTER>
<table width="640" border="0" cellspacing="0" cellpadding="0">
	<TR VALIGN="TOP"> 
		<TD> 
			
								
				
				<DIV ALIGN="CENTER">
	<IMG VSPACE="7" SRC="/icons/content/v2_case_rec_head.gif" ALT="Case Records of the Massachusetts General Hospital">
	  
	  
	    
	    
	      <BR><IMG SRC="/icons/content/series/case_weekly_ednames.gif" ALT="Editor's Names">
	    
	  
	

	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	

				
          		<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="640">
				<TR>
					<TD VALIGN="TOP" NOWRAP><A HREF="/cgi/content/short/349/18/1738?query=prevarrow"><IMG ALT="Previous" WIDTH="9" HEIGHT="8" HSPACE="4" BORDER="0" SRC="/icons/v2_toc_arrowprev.gif"><FONT SIZE="-1" FACE="arial,helvetica">Previous</FONT></A></TD>
          			<TD ALIGN="CENTER" VALIGN="TOP"><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0">
						<TH ALIGN="RIGHT" VALIGN="TOP" NOWRAP>Volume 349:1750-1760</TH>
						<TD NOWRAP><IMG ALT="" WIDTH="30" HEIGHT="30" SRC="/icons/spacer.gif"></TD>
						<TH VALIGN="TOP" NOWRAP><A HREF="/content/vol349/issue18/index.shtml"><FONT COLOR="#000000">October 30, 2003</FONT></A></TH>
						<TD NOWRAP><IMG ALT="" WIDTH="30" HEIGHT="30" SRC="/icons/spacer.gif"></TD>
						<TH ALIGN="LEFT" VALIGN="TOP" NOWRAP>Number 18</TH>
					</TR></TABLE></TD>
					<TD VALIGN="TOP" ALIGN="RIGHT" NOWRAP><A HREF="/cgi/content/short/349/18/1762?query=nextarrow"><FONT SIZE="-1" FACE="arial,helvetica">Next</FONT><IMG ALT="Next" WIDTH="9" HEIGHT="8" HSPACE="4" BORDER="0" SRC="/icons/v2_toc_arrownext.gif"></A></TD>
          		</TR>
				</TABLE>
				
          		</DIV>
      			
      		

      </TD>
    </TR>
</TABLE>
</CENTER>
<P>





<div align="center"><b><FONT SIZE="+2" face="Arial, Helvetica, sans-serif">Case 34-2003 &#151; A 45-Year-Old Woman with a Family History of Colonic Polyps and Cancer</FONT></B><BR></div>


	
	<CENTER><FONT SIZE="+1"><I>
	
	
			Daniel C. Chung, M.D., Mari Mino, M.D., and Kristen M. Shannon, M.S., C.G.C.
		
	</I></FONT></CENTER>







<P>

 



 
		                    



 
	 

<table border="0" cellpadding="0" cellspacing="0" width="200" ALIGN="RIGHT">
<tr>
<td width="20">&nbsp;</td>
<TD BGCOLOR="336699">

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="1">

	<TR VALIGN="top">
		<td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
			<img src="/icons/v3_this_article.gif" alt="This Article" width="73" height="8" BORDER="0"><BR>
			<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
	</tr><tr>
		<td> 
                <table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
		<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
		
		
		
		

		
		 

		
		<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b>
			
			
			
				
						
						<A class="contentboxLinks" HREF="/cgi/reprint/349/18/1750.pdf">PDF</A></b></font></td></tr>
		
		<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/ac_external_ref?link_type=pda_mms&doi=10.1056%2FNEJMcpc030023">PDA Full Text</A></b></font></td></tr>
		
		
		

		

		

		 
		
		



	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	</table>
        </td>
        </tr>









	<tr> 
	<td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
	<img src="/icons/v3_tools_service.gif" alt="Tools and Services" width="103" height="9" align="absmiddle"><BR>
	<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
	</tr>
	<tr> 
	<td> 
	<table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	
		
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/folders?action=addtofolder&wherefrom=JOURNALS&wrapped_id=nejm;349/18/1750">Add to Personal Archive</A></b></font></td></tr>
	
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/citmgr?gca=nejm;349/18/1750">Add to Citation Manager</A></b></font></td></tr>
	
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/mailafriend?url=http://content.nejm.org/cgi/content/short/349/18/1750&title=Case+34-2003+-+A+45-Year-Old+Woman+with+a+Family+History+of+Colonic+Polyps+and+Cancer"><b>Notify a Friend</b></a></b></font></td></tr>

	
        <tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=nejm;349/18/1750&return_type=article&return_url=%2Fcgi%2Fcontent%2Ffull%2F349%2F18%2F1750">E-mail When Cited</A></b></font></td></tr>

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/ac_external_ref?link_type=letters_mms&doi=10.1056%2FNEJMcpc030023">E-mail When Letters Appear</A></b></font></td></tr>
	
	
	
	

	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	</table>
        </td>
        </tr>



        <tr>
        <td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
	<img src="/icons/v3_more_information.gif" alt="More Information" width="116" height="8" align="absmiddle"><BR>
	<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
        </tr>
        <tr>
        <td>
        <table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
        

	

	

	

	

	

	

	

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/search?qbe=nejm;349/18/1750&journalcode=nejm&minscore=5000">Find Similar Articles</A></b></font></td></tr>

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/external_ref?access_num=14585944&link_type=PUBMED" onClick="ISIwin('ISI')" TARGET="ISI">PubMed Citation</A></b></font></td></tr>

<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
</table>
</td>
</tr>

        
        
</table>
</table>	 <!-- end of outer content box1 -->
</TABLE>	 <!-- end of outer content box2 -->










 





	
	
	
	
	
	
	
	
	
		


<!-- <CENTER><H2><FONT FACE="arial, helvetica">
Case 34-2003
</FONT></H2> </CENTER> -->
<!-- <H3>
A 45-Year-Old Woman with a Family History of Colonic Polyps and Cancer
</H3> -->


<!--<CENTER><I>
</NOBR><NOBR>Daniel C. Chung, M.D.</NOBR>, 
<NOBR>Mari Mino, M.D.</NOBR> and 
<NOBR>Kristen M. Shannon, M.S., C.G.C.</NOBR>
</I></CENTER><P>
-->


<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Presentation of Case</STRONG></FONT><P>

A 45-year-old woman came to the outpatient clinic for counseling<SUP> </SUP>because of concern about a family history of colonic polyps<SUP> </SUP>and cancer.<SUP> </SUP><P>

The patient felt well and had had no abdominal pain, change<SUP> </SUP>in bowel habits, rectal bleeding, or weight loss. She had had<SUP> </SUP>no operations and took no medications. A colonoscopic examination<SUP> </SUP>had been performed for screening purposes four years earlier,<SUP> </SUP>and no polyps had been identified. She did not smoke and rarely<SUP> </SUP>consumed alcohol.<SUP> </SUP><P>

The patient's mother was 80 years old and had been given a diagnosis<SUP> </SUP>of colon cancer at 75 years of age. The patient's father was<SUP> </SUP>74 years old. At 53 years of age, he had had recurrent episodes<SUP> </SUP>of pancreatitis, and a workup had revealed a large villous adenoma<SUP> </SUP>of the ampulla of Vater, which was surgically resected. A recurrence<SUP> </SUP>of the lesion necessitated a Whipple procedure that was performed<SUP> </SUP>at 56 years of age. Colonoscopy was performed, and more than<SUP> </SUP>50 small adenomas were identified in the right side of the colon.<SUP> </SUP>Two large adenomas measuring more than 1 cm in diameter were<SUP> </SUP>seen, one at the hepatic flexure and one in the rectosigmoid<SUP> </SUP>colon. When the patient's father was 57 years old, a subtotal<SUP> </SUP>colectomy with an ileosigmoid anastomosis was performed. Multiple<SUP> </SUP>fundic-gland polyps were also identified in his stomach. He<SUP> </SUP>had been followed thereafter with sigmoidoscopic examinations<SUP> </SUP>every one to two years, and several adenomas had been removed<SUP> </SUP>each time.<SUP> </SUP><P>

The patient had three paternal aunts; breast cancer had developed<SUP> </SUP>in one at 80 years of age, bladder cancer had been diagnosed<SUP> </SUP>in another at 79 years of age, and the third was alive and healthy<SUP> </SUP>at 79 years of age. The patient's paternal grandfather had died<SUP> </SUP>at 72 years of age without a diagnosis of cancer, but her paternal<SUP> </SUP>grandfather's sister had died of colon cancer in her 30s. Her<SUP> </SUP>paternal grandmother had died at 35 years of age from unknown<SUP> </SUP>causes.<SUP> </SUP><P>

The patient's brother had had a normal colonoscopic examination<SUP> </SUP>at 35 years of age. However, multiple adenomas were later identified<SUP> </SUP>in the cecum when he was 45 years old, and a right hemicolectomy<SUP> </SUP>was performed. The pathological analysis confirmed the presence<SUP> </SUP>of 50 to 100 diminutive adenomas in the cecum and the right<SUP> </SUP>side of the colon. Annual follow-up colonoscopic examinations<SUP> </SUP>revealed several diminutive adenomas; an endoscopic examination<SUP> </SUP>of the stomach and duodenum revealed fundic-gland polyps in<SUP> </SUP>the stomach and a tubular adenoma in the duodenum. The patient's<SUP> </SUP>sister was 46 years old, had no known medical problems, and<SUP> </SUP>had never undergone colonoscopy.<SUP> </SUP><P>

The patient had two children, 13 and 11 years of age, both of<SUP> </SUP>whom were healthy. The physical examination and results of routine<SUP> </SUP>laboratory studies performed by the patient's primary care physician<SUP> </SUP>were normal.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Pathological Discussion</STRONG></FONT><P>

<I>Dr. Mari Mino</I>: Specimens from the patient's father are shown<SUP> </SUP>in <A HREF="#F1">Figure 1</A>. The Whipple procedure performed when he was 56<SUP> </SUP>years old disclosed a tubulovillous adenoma in the ampulla of<SUP> </SUP>Vater, measuring 0.8 cm in diameter, which extended into the<SUP> </SUP>main pancreatic duct (<A HREF="#F1">Figure 1A</A>). A right colectomy that was<SUP> </SUP>performed a year later disclosed a tubulovillous adenoma, 5.0<SUP> </SUP>cm in diameter, in the ascending colon; a tubulovillous adenoma,<SUP> </SUP>2.0 cm in diameter, at the hepatic flexure; and more than 50<SUP> </SUP>small tubular adenomas proximal to the hepatic flexure (<A HREF="#F1">Figure 1B</A><SUP> </SUP>and <A HREF="#F1">Figure 1C</A>). Multiple gastric polyps were detected when<SUP> </SUP>the patient's father was 72 years old; a biopsy of one of them<SUP> </SUP>revealed a fundic-gland polyp with superficial adenomatous changes<SUP> </SUP>(<A HREF="#F1">Figure 1D</A>).<SUP> </SUP><P>

<A NAME="F1"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<A HREF="/cgi/content/full/349/18/1750/F1"><IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=127 HEIGHT=128 SRC="/content/vol349/issue18/images/small/12f1.gif" ALT=" "></A><BR>

<STRONG>View larger version</STRONG> (120K):<BR>
<NOBR><A HREF="/cgi/content/full/349/18/1750/F1">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/349/18/1750/F1"
    onClick="startTarget('F1', 587, 640); this.href='/cgi/content-nw/full/349/18/1750/F1'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="F1">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 1.</B> Specimens from the Patient's Father.<P>

A polypoid lesion, 0.8 cm in diameter, at the ampulla of Vater (Panel A) is a tubulovillous adenoma occupying the ampulla (arrows) and extending into the main pancreatic duct (arrowheads; hematoxylin and eosin, <FONT FACE="arial,helvetica">x</FONT>30). A high-power view (inset) shows a clear boundary (arrow) between normal duodenal mucosa and the dysplastic area (<FONT FACE="arial,helvetica">x</FONT>40). A gross image of a specimen obtained during the right colectomy (Panel B) shows a mass, 5.0 cm in diameter, in the ascending colon (arrow), a polyp measuring 2.0 cm in diameter at the hepatic flexure (arrowhead), and 50 to 100 small polyps. A histologic section of the 5.0-cm mass reveals a tubulovillous adenoma (Panel C; hematoxylin and eosin, <FONT FACE="arial,helvetica">x</FONT>30). A gastric polyp (Panel D, <FONT FACE="arial,helvetica">x</FONT>80) has features of a fundic-gland polyp with a proliferation of fundic glands near the mucosal surface and cystically dilated glands. The mucosal surface (inset) is replaced by dysplastic epithelium (<FONT FACE="arial,helvetica">x</FONT>250).<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


The specimen obtained from the patient's brother during the<SUP> </SUP>right hemicolectomy performed when he was 45 years old revealed<SUP> </SUP>50 to 100 rather small, flat polyps carpeting the cecum and<SUP> </SUP>the right side of the colon (<A HREF="#F2">Figure 2</A>). These included both<SUP> </SUP>serrated adenomas and tubular adenomas.<SUP> </SUP><P>

<A NAME="F2"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<A HREF="/cgi/content/full/349/18/1750/F2"><IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=58 HEIGHT=128 SRC="/content/vol349/issue18/images/small/12f2.gif" ALT=" "></A><BR>

<STRONG>View larger version</STRONG> (53K):<BR>
<NOBR><A HREF="/cgi/content/full/349/18/1750/F2">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/349/18/1750/F2"
    onClick="startTarget('F2', 348, 640); this.href='/cgi/content-nw/full/349/18/1750/F2'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="F2">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 2.</B> Specimens from the Patient's Brother.<P>

A gross image of the specimen obtained during the right colectomy (Panel A) shows 50 to 100 small polyps carpeting the cecum and the right side of the colon. A "flat" adenoma (Panel B; hematoxylin and eosin, <FONT FACE="arial,helvetica">x</FONT>50) shows superficial involvement of the colonic mucosa by adenomatous crypts. The thickness of the adenoma is less than twice that of adjacent normal mucosa. A serrated adenoma (Panel C) is characterized by a proliferation of dysplastic glands with hypermature, eosinophilic cytoplasm, forming a serrated configuration (hematoxylin and eosin, <FONT FACE="arial,helvetica">x</FONT>55).<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


Syndromes of colonic polyposis are classified into two types:<SUP> </SUP>nonadenomatous and adenomatous. Nonadenomatous polyposis syndromes<SUP> </SUP>include Peutz&#150;Jegher's syndrome, Cowden's syndrome, juvenile<SUP> </SUP>polyposis syndrome, and Cronkhite&#150;Canada syndrome, and<SUP> </SUP>they are distinguished from adenomatous polyposis syndromes<SUP> </SUP>by the morphologic features of the polyps (i.e., hamartomatous<SUP> </SUP>polyps or juvenile polyps) and the presence and type of extracolonic<SUP> </SUP>manifestations.<A HREF="#R1"><SUP>1</SUP></A><SUP> </SUP><P>

Familial adenomatous polyposis is the best-recognized adenomatous<SUP> </SUP>polyposis syndrome. It can be further classified into two types:<SUP> </SUP>classic familial adenomatous polyposis and attenuated familial<SUP> </SUP>adenomatous polyposis. Classic familial adenomatous polyposis<SUP> </SUP>is characterized by the presence of numerous polypoid adenomas<SUP> </SUP>&#151; usually numbering in the thousands &#151; located throughout<SUP> </SUP>the colon.<A HREF="#R1"><SUP>1</SUP></A><SUP>,</SUP><A HREF="#R2"><SUP>2</SUP></A> Attenuated familial adenomatous polyposis is characterized<SUP> </SUP>by the presence of fewer colonic polyps (usually fewer than<SUP> </SUP>100), which are often flat and tend to be located proximal to<SUP> </SUP>the splenic flexure.<A HREF="#R1"><SUP>1</SUP></A><SUP>,</SUP><A HREF="#R2"><SUP>2</SUP></A><SUP>,</SUP><A HREF="#R3"><SUP>3</SUP></A><SUP>,</SUP><A HREF="#R4"><SUP>4</SUP></A><SUP>,</SUP><A HREF="#R5"><SUP>5</SUP></A><SUP> </SUP><P>

Extracolonic tumors are found in both disorders. Gastric fundic-gland<SUP> </SUP>polyps, duodenal adenomas, and ampullary adenomas are the most<SUP> </SUP>common, and the onset of fundic-gland polyps may actually precede<SUP> </SUP>that of colonic adenomas in patients with attenuated familial<SUP> </SUP>adenomatous polyposis.<A HREF="#R4"><SUP>4</SUP></A> In the classic form of the disorder,<SUP> </SUP>papillary thyroid tumors, abdominal desmoid tumors, osteomas,<SUP> </SUP>epidermoid cysts, and hepatoblastomas also occur, but these<SUP> </SUP>tumors are uncommon in patients with the attenuated form of<SUP> </SUP>the disorder. The eponym Gardner's syndrome was originally applied<SUP> </SUP>to cases in which there were bone and soft-tissue abnormalities<SUP> </SUP>in addition to the phenotype of familial adenomatous polyposis.<A HREF="#R1"><SUP>1</SUP></A><SUP>,</SUP><A HREF="#R2"><SUP>2</SUP></A><SUP> </SUP>Because the genetic basis of familial adenomatous polyposis<SUP> </SUP>is identical to that of Gardner's syndrome, this distinction<SUP> </SUP>does not appear to be meaningful.<SUP> </SUP><P>

The pathological features of the polyps and their anatomical<SUP> </SUP>distribution in this family are most consistent with attenuated<SUP> </SUP>familial adenomatous polyposis.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Differential Diagnosis</STRONG></FONT><P>

<I>Dr. Daniel C. Chung</I>: The patient in this case is known to me,<SUP> </SUP>and I am aware of the diagnosis. The most compelling feature<SUP> </SUP>is the family history of multiple adenomatous polyps (<A HREF="#F3">Figure 3</A>).<SUP> </SUP>The overall prevalence of colonic adenomas among persons<SUP> </SUP>50 years of age is estimated to be less than 25 percent.<A HREF="#R6"><SUP>6</SUP></A> Three<SUP> </SUP>or fewer synchronous adenomas are typically identified. The<SUP> </SUP>finding of more than 50 polyps is consistent with a polyposis<SUP> </SUP>syndrome, and its presence in both the patient's father (family<SUP> </SUP>member II-2) and her brother (III-1) indicates an inheritance<SUP> </SUP>pattern that is autosomal dominant. The colon cancer diagnosed<SUP> </SUP>in the patient's mother (II-1) at 75 years of age probably represents<SUP> </SUP>a sporadic case, since she did not have multiple polyps and<SUP> </SUP>there is no compelling history of colon cancer among her relatives.<SUP> </SUP><P>

<A NAME="F3"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<A HREF="/cgi/content/full/349/18/1750/F3"><IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=128 HEIGHT=120 SRC="/content/vol349/issue18/images/small/12f3.gif" ALT=" "></A><BR>

<STRONG>View larger version</STRONG> (27K):<BR>
<NOBR><A HREF="/cgi/content/full/349/18/1750/F3">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/349/18/1750/F3"
    onClick="startTarget('F3', 590, 613); this.href='/cgi/content-nw/full/349/18/1750/F3'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="F3">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 3.</B> The Patient's Pedigree.<P>

The arrow indicates the patient (proband). The proband's brother and father (green symbols) were given diagnoses of adenomas of the colon (CO-A), duodenum (DUO-A), and ampulla (AMP-A). The proband's mother and paternal great aunt (blue symbols) were given diagnoses of colon cancer (CO). Circles represent female family members, squares male family members, and slashes dead family members; BR denotes breast cancer, and BL bladder cancer. The number after each diagnosis is the age at which the diagnosis was made.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


Approximately 25 percent of cases of colon cancer are associated<SUP> </SUP>with a familial predisposition. A recent meta-analysis estimated<SUP> </SUP>that the relative risk of colon cancer is 2.25 if colon cancer<SUP> </SUP>is diagnosed in a first-degree relative<A HREF="#R7"><SUP>7</SUP></A> and 4.25 if there are<SUP> </SUP>two affected first-degree relatives. If these diagnoses are<SUP> </SUP>made at an early age (before 45 years), the relative risk is<SUP> </SUP>estimated to be 3.87. Similarly, the relative risk is 1.99 if<SUP> </SUP>a first-degree relative has been given a diagnosis of a colonic<SUP> </SUP>adenoma. The highest risk of colon cancer, however, is that<SUP> </SUP>found in families that exhibit features of familial adenomatous<SUP> </SUP>polyposis or hereditary nonpolyposis colorectal cancer, both<SUP> </SUP>of which are autosomal dominant disorders.<A HREF="#R8"><SUP>8</SUP></A> Each family member<SUP> </SUP>has a 50 percent chance of inheriting the disorder, and among<SUP> </SUP>those who do inherit it, the risk of colon cancer approaches<SUP> </SUP>100 percent.<SUP> </SUP><P>

<STRONG>Familial Adenomatous Polyposis and Attenuated Familial Adenomatous Polyposis</STRONG><P>

The diagnosis of familial adenomatous polyposis is straightforward;<SUP> </SUP>the characteristic carpeting of the colon with hundreds or thousands<SUP> </SUP>of polyps may be observed by the second or third decade of life.<SUP> </SUP>The delayed appearance of only a moderate number of polyps is<SUP> </SUP>seen in the attenuated form of the disorder. This form was initially<SUP> </SUP>described as the hereditary flat-adenoma syndrome, but it has<SUP> </SUP>since been recognized that the adenomas may be either flat or<SUP> </SUP>polypoid.<A HREF="#R4"><SUP>4</SUP></A><SUP>,</SUP><A HREF="#R9"><SUP>9</SUP></A><SUP>,</SUP><A HREF="#R10"><SUP>10</SUP></A> The natural history of attenuated familial adenomatous<SUP> </SUP>polyposis is continuing to be defined, but the risk of colon<SUP> </SUP>cancer among persons with the disorder is estimated to be between<SUP> </SUP>80 and 100 percent.<SUP> </SUP><P>

The diagnosis of attenuated familial adenomatous polyposis may<SUP> </SUP>be overlooked for several reasons. The polyposis is not florid,<SUP> </SUP>and the age at onset is late. In addition, there is marked phenotypic<SUP> </SUP>heterogeneity, not only among different kindreds, but also within<SUP> </SUP>an individual kindred. Some persons may present with as few<SUP> </SUP>as 1 to 10 polyps or with colon cancer as late as 60 to 70 years<SUP> </SUP>of age. Thus, the clinical features may be indistinguishable<SUP> </SUP>from those of sporadic cases. For these reasons, attenuated<SUP> </SUP>familial adenomatous polyposis is probably underdiagnosed, and<SUP> </SUP>its true prevalence is unknown. A heightened clinical awareness,<SUP> </SUP>in combination with a careful family history taking, is the<SUP> </SUP>essential first step in the recognition of this syndrome.<SUP> </SUP><P>

<STRONG>Genetic Basis of Familial Adenomatous Polyposis</STRONG><P>

Familial adenomatous polyposis and attenuated familial adenomatous<SUP> </SUP>polyposis both result from germ-line mutations in the <I>APC</I> tumor-suppressor<SUP> </SUP>gene, which was one of the first inherited cancer-susceptibility<SUP> </SUP>genes to be cloned, in 1991. Mutations in <I>APC</I> activate the Wnt<SUP> </SUP>signaling pathway, which controls cell-cycle progression and<SUP> </SUP>apoptosis. Nearly 400 different germ-line mutations have been<SUP> </SUP>identified throughout the <I>APC</I> gene,<A HREF="#R11"><SUP>11</SUP></A> and more than 80 percent<SUP> </SUP>result in a premature stop codon, which leads to the synthesis<SUP> </SUP>of a truncated protein that is nonfunctional.<SUP> </SUP><P>

There are fascinating correlations between the location of the<SUP> </SUP><I>APC</I> mutation and the clinical phenotype (<A HREF="#F4">Figure 4</A>). Thirty-four<SUP> </SUP>different mutations causing attenuated familial adenomatous<SUP> </SUP>polyposis have been reported to date, and they are clustered<SUP> </SUP>either at the far 5' end or the 3' end of the coding region<SUP> </SUP>of the <I>APC</I> gene.<A HREF="#R10"><SUP>10</SUP></A> In contrast, the mutations involved in classic<SUP> </SUP>familial adenomatous polyposis are located in the central region,<SUP> </SUP>and mutations between codons 1250 and 1464 are associated with<SUP> </SUP>particularly severe polyposis. Abdominal desmoid tumors are<SUP> </SUP>more likely to occur in persons with mutations between codons<SUP> </SUP>1445 and 1578. A point mutation in which lysine is substituted<SUP> </SUP>for isoleucine at codon 1307 (I1307K) has been identified in<SUP> </SUP>6 percent of the Ashkenazi Jewish population and is associated<SUP> </SUP>with an increase by a factor of less than two in the risk of<SUP> </SUP>cancer without accompanying polyposis.<A HREF="#R12"><SUP>12</SUP></A><SUP> </SUP><P>

<A NAME="F4"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<A HREF="/cgi/content/full/349/18/1750/F4"><IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=128 HEIGHT=68 SRC="/content/vol349/issue18/images/small/12f4.gif" ALT=" "></A><BR>

<STRONG>View larger version</STRONG> (14K):<BR>
<NOBR><A HREF="/cgi/content/full/349/18/1750/F4">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/349/18/1750/F4"
    onClick="startTarget('F4', 590, 435); this.href='/cgi/content-nw/full/349/18/1750/F4'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="F4">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 4.</B> Correlations between the <I>APC</I> Genotype and the Clinical Phenotype.<P>

The 15 exons of the <I>APC</I> gene are shown. The locations of germ-line mutations that are associated with specific clinical phenotypes are indicated by the dark horizontal lines. Thirty-four mutations causing attenuated familial adenomatous polyposis (FAP) have been reported to date; these are clustered either at the far 5' end (before codon 436) or at the 3' end (after codon 1596) of the <I>APC</I> gene. In contrast, mutations causing classic familial adenomatous polyposis are located in the central region, and mutations between codons 1250 and 1464 are associated with particularly severe polyposis. Abdominal desmoid tumors are more likely in persons with mutations between codons 1445 and 1578.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


The molecular mechanisms that explain why certain <I>APC</I> mutations<SUP> </SUP>result in a classic phenotype and others in an attenuated phenotype<SUP> </SUP>are currently being elucidated. Most models are predicated on<SUP> </SUP>the "two-hit hypothesis" &#151; which states that both alleles<SUP> </SUP>of <I>APC</I> must be inactivated in order to initiate tumorigenesis.<SUP> </SUP>In classic familial adenomatous polyposis, affected persons<SUP> </SUP>inherit one mutant <I>APC</I> gene that produces a nonfunctional protein,<SUP> </SUP>and the second normal, or wild-type, allele is typically inactivated<SUP> </SUP>by a chromosomal deletion, leading to a loss of heterozygosity.<SUP> </SUP>In some cases, the mutant APC protein may even behave in a dominant<SUP> </SUP>negative manner, functionally inactivating the remaining wild-type<SUP> </SUP>protein.<A HREF="#R13"><SUP>13</SUP></A> In contrast, mutations that give rise to attenuated<SUP> </SUP>familial adenomatous polyposis result in proteins that appear<SUP> </SUP>to be partly functional.<A HREF="#R14"><SUP>14</SUP></A> Consequently, somatic mutations must<SUP> </SUP>occur to inactivate not only the wild-type allele but also the<SUP> </SUP>allele with the mutation for attenuated familial adenomatous<SUP> </SUP>polyposis (<A HREF="#F5">Figure 5</A>).<A HREF="#R15"><SUP>15</SUP></A> The additional time required to acquire<SUP> </SUP>these two somatic mutations is predicted to be far greater than<SUP> </SUP>that required to inactivate one allele, and this difference<SUP> </SUP>may account for the later presentation in persons with attenuated<SUP> </SUP>familial adenomatous polyposis, as compared with that in classic<SUP> </SUP>familial adenomatous polyposis. The molecular basis for the<SUP> </SUP>right-sided predominance of polyps, however, is entirely unknown.<SUP> </SUP><P>

<A NAME="F5"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<A HREF="/cgi/content/full/349/18/1750/F5"><IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=74 HEIGHT=128 SRC="/content/vol349/issue18/images/small/12f5.gif" ALT=" "></A><BR>

<STRONG>View larger version</STRONG> (30K):<BR>
<NOBR><A HREF="/cgi/content/full/349/18/1750/F5">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/349/18/1750/F5"
    onClick="startTarget('F5', 406, 640); this.href='/cgi/content-nw/full/349/18/1750/F5'"
 	onMouseOver="window.status='View figure in a separate window'; return true"
 	TARGET="F5">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Figure 5.</B> Mechanisms of Inactivation of the <I>APC</I> Gene in Classic and Attenuated Familial Adenomatous Polyposis (FAP).<P>

Both copies of chromosome 5 are shown. In classic familial adenomatous polyposis (Panel A), the biallelic inactivation of <I>APC</I> is typically achieved by the combination of an inherited germ-line mutation in one allele (black X) and a chromosomal deletion of the remaining wild-type allele; this is called loss of heterozygosity. In some cases, the germ-line <I>APC</I> mutation (red X) can result in the production of a protein that can inhibit the activity of the wild-type protein (white X). This dominant negative effect functionally results in biallelic inactivation. In attenuated familial adenomatous polyposis (Panel B), the mechanism of <I>APC</I> inactivation varies. Germ-line mutations involved in attenuated familial adenomatous polyposis may lead to the formation of alternative APC proteins that are initiated from an internal translation site that is located distal to the truncating mutation. This alternative APC protein does have functional activity. Because of this residual gene activity, an additional "hit" is necessary to fully inactivate <I>APC</I> (Panel C). This third hit is indicated by the blue X. The second hit is often an intragenic mutation (green X) that inactivates the wild-type <I>APC</I> allele, rather than a large chromosomal deletion as in classic familial adenomatous polyposis. The red X represents the inherited <I>APC</I> mutation.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


<STRONG>Hereditary Nonpolyposis Colorectal Cancer</STRONG><P>

An alternative diagnostic consideration in this case is the<SUP> </SUP>hereditary nonpolyposis colorectal cancer syndrome, another<SUP> </SUP>autosomal dominant condition that is characterized by the occurrence<SUP> </SUP>of a limited number of adenomas (<A HREF="#T1">Table 1</A>). The clinical and<SUP> </SUP>genetic features of hereditary nonpolyposis colorectal cancer<SUP> </SUP>have been detailed elsewhere.<A HREF="#R8"><SUP>8</SUP></A><SUP>,</SUP><A HREF="#R16"><SUP>16</SUP></A> As in attenuated familial<SUP> </SUP>adenomatous polyposis, the adenomas and cancers are located<SUP> </SUP>preferentially in the right side of the colon. However, the<SUP> </SUP>mean age at the diagnosis of colon cancer is lower (45 years),<SUP> </SUP>the number of adenomas is much smaller, and the polyps do not<SUP> </SUP>occur in a carpet-like pattern. According to the Amsterdam criteria<SUP> </SUP>of 1991, a diagnosis of hereditary nonpolyposis colorectal cancer<SUP> </SUP>can be made when three or more family members have a diagnosis<SUP> </SUP>of colorectal cancer, when one of those family members is a<SUP> </SUP>first-degree relative of the other two, and when one of the<SUP> </SUP>cases is diagnosed before 50 years of age. There is a strong<SUP> </SUP>association between hereditary nonpolyposis colorectal cancer<SUP> </SUP>and tumors of the endometrium, urinary tract, ovary, stomach,<SUP> </SUP>and biliary tract, but not between this syndrome and fundic-gland<SUP> </SUP>polyps or ampullary tumors. For all these reasons, this diagnosis<SUP> </SUP>is unlikely to be correct in this case.<SUP> </SUP><P>

<A NAME="T1"><!-- null --></A>
<TABLE CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=#E8E8D1><TD><TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=#E8E8D1><TD ALIGN=center VALIGN=top BGCOLOR=ffffff>
<STRONG>View this table:</STRONG><BR>
<NOBR><A HREF="/cgi/content/full/349/18/1750/T1">[in this window]</A><BR>
<A HREF="/cgi/content-nw/full/349/18/1750/T1"
    onClick="startTarget('T1', 950, 605); this.href='/cgi/content-nw/full/349/18/1750/T1'"
 	onMouseOver="window.status='View table in a separate window'; return true"
 	TARGET="T1">[in a new window]</A><BR>&#160;</NOBR>
</TD><TD ALIGN=left VALIGN=top>
<B>Table 1.</B> Characteristics of Classic Familial Adenomatous Polyposis, Attenuated Familial Adenomatous Polyposis, and Hereditary Nonpolyposis Colorectal Cancer.<P>


</TD></TR></TABLE></TD></TR></TABLE>&nbsp;<BR>


<STRONG>Colonic Adenomas and Germ-Line Mutations in <I>MYH</I></STRONG><P>

A recently described syndrome of multiple colonic adenomas due<SUP> </SUP>to alterations in the <I>MYH</I> gene also deserves consideration.<A HREF="#R17"><SUP>17</SUP></A><SUP> </SUP><I>MYH</I> repairs oxidized deoxyguanine nucleotides, and in the study<SUP> </SUP>by Sieber et al.,<A HREF="#R17"><SUP>17</SUP></A> 29 percent of persons who had more than<SUP> </SUP>15 colonic adenomas were found to harbor homozygous germ-line<SUP> </SUP>mutations in <I>MYH</I>. Some of these persons even had features of<SUP> </SUP>classic familial adenomatous polyposis. Much remains to be learned<SUP> </SUP>about the full clinical spectrum of this disorder, but its autosomal<SUP> </SUP>recessive pattern of inheritance makes it an unlikely diagnosis<SUP> </SUP>in this case.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Summary and Diagnosis</STRONG></FONT><P>

In this patient's family, the autosomal dominant pattern of<SUP> </SUP>inheritance, the right-sided oligopolyposis occurring during<SUP> </SUP>the fifth or sixth decade of life, and the associated ampullary<SUP> </SUP>tumors and fundic-gland polyps all point convincingly to the<SUP> </SUP>diagnosis of attenuated familial adenomatous polyposis. There<SUP> </SUP>is a clear-cut pattern of inheritance in two generations (<A HREF="#F3">Figure 3</A>).<SUP> </SUP>The penetrance of classic familial adenomatous polyposis<SUP> </SUP>is 100 percent. The patient's father (family member II-2) may<SUP> </SUP>have had a new mutation, since neither of his parents had polyposis<SUP> </SUP>or colon cancer. Such new cases account for approximately 20<SUP> </SUP>percent of families with familial adenomatous polyposis. However,<SUP> </SUP>the possibility that the patient's paternal grandfather was<SUP> </SUP>a silent carrier cannot be entirely ruled out, since the penetrance<SUP> </SUP>of attenuated familial adenomatous polyposis has not yet been<SUP> </SUP>defined. This patient has a 50 percent risk of having attenuated<SUP> </SUP>familial adenomatous polyposis. Although she had a normal colonoscopy<SUP> </SUP>four years before presentation, this does not rule out the diagnosis,<SUP> </SUP>because the age of onset of polyps among persons with this disorder<SUP> </SUP>varies widely. A more definitive assessment of the patient's<SUP> </SUP>risk has obvious implications not only for her, but also for<SUP> </SUP>her children.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Dr. Daniel C. Chung's Diagnosis</STRONG></FONT><P>

Attenuated familial adenomatous polyposis with a germ-line mutation<SUP> </SUP>in the <I>APC</I> gene.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Discussion of Management</STRONG></FONT><P>

<I>Dr. Chung</I>: The care of patients with known or suspected mutations<SUP> </SUP>in the <I>APC</I> gene involves intensive surveillance for cancer,<SUP> </SUP>chemoprevention, and more recently, genetic testing. Annual<SUP> </SUP>screening for colonic polyps and cancer is required for all<SUP> </SUP>known or suspected carriers of attenuated familial adenomatous<SUP> </SUP>polyposis. Colonoscopy rather than sigmoidoscopy is necessary<SUP> </SUP>because of the right-sided predominance of the polyps. Because<SUP> </SUP>of the variable age at the onset of polyps, there is no standardized<SUP> </SUP>age at which to begin colonoscopic screening. One set of conservative<SUP> </SUP>guidelines recommends beginning as early as 15 to 25 years of<SUP> </SUP>age,<A HREF="#R10"><SUP>10</SUP></A><SUP>,</SUP><A HREF="#R18"><SUP>18</SUP></A> and screening must continue throughout life. Because<SUP> </SUP>of the heterogeneity in the number of polyps in persons with<SUP> </SUP>attenuated familial adenomatous polyposis, prophylactic colectomy<SUP> </SUP>is not considered to be mandatory, as it is for persons with<SUP> </SUP>classic familial adenomatous polyposis. However, in cases in<SUP> </SUP>which all polyps cannot be removed endoscopically or in which<SUP> </SUP>cancer is diagnosed, a subtotal colectomy with ileorectal anastomosis<SUP> </SUP>is recommended, followed by continued endoscopic surveillance<SUP> </SUP>of any remaining rectal mucosa.<SUP> </SUP><P>

The second leading cause of cancer-related death in patients<SUP> </SUP>with familial adenomatous polyposis is duodenal and ampullary<SUP> </SUP>cancer. Thus, lifelong surveillance for cancers that can arise<SUP> </SUP>in these extracolonic sites is also required. It is recommended<SUP> </SUP>that an upper endoscopy be performed every one to three years,<SUP> </SUP>with a biopsy of the ampulla, even if it appears to be normal.<SUP> </SUP>Fundic-gland polyps have traditionally been thought to have<SUP> </SUP>no malignant potential, but this premise is being challenged,<SUP> </SUP>since reports have suggested that there may be an increased<SUP> </SUP>risk of gastric adenocarcinoma among patients with attenuated<SUP> </SUP>familial adenomatous polyposis.<A HREF="#R19"><SUP>19</SUP></A> These guidelines apply not<SUP> </SUP>only to known mutation carriers but also to family members who<SUP> </SUP>are at risk but whose carrier status remains unknown.<SUP> </SUP><P>

<STRONG>Chemopreventive Agents</STRONG><P>

Adenomatous polyps and colorectal cancers greatly overexpress<SUP> </SUP>cyclooxygenase-2,<A HREF="#R20"><SUP>20</SUP></A> which regulates prostaglandin synthesis.<SUP> </SUP>Overproduction of prostaglandin E<SUB>2</SUB>, in particular, may be key<SUP> </SUP>in the pathogenesis of colon cancer.<A HREF="#R21"><SUP>21</SUP></A> Agents that inhibit the<SUP> </SUP>enzymatic activity of cyclooxygenase-2 (sulindac and celecoxib)<SUP> </SUP>have been tested as chemopreventive agents in randomized, controlled<SUP> </SUP>trials involving patients with familial adenomatous polyposis<SUP> </SUP>who had a residual rectum. Both of these agents have been shown<SUP> </SUP>to reduce the number and size of polyps,<A HREF="#R22"><SUP>22</SUP></A><SUP>,</SUP><A HREF="#R23"><SUP>23</SUP></A><SUP>,</SUP><A HREF="#R24"><SUP>24</SUP></A> although they<SUP> </SUP>do not appear to prevent the initial formation of colonic polyps<A HREF="#R25"><SUP>25</SUP></A><SUP> </SUP>or to have as potent an effect on duodenal polyps.<A HREF="#R26"><SUP>26</SUP></A> It must<SUP> </SUP>be emphasized that these agents cannot be considered to be definitive<SUP> </SUP>therapy and will not replace endoscopic surveillance and carefully<SUP> </SUP>timed surgery. Nevertheless, they have assumed an important<SUP> </SUP>adjunctive role in the management of familial adenomatous polyposis<SUP> </SUP>and attenuated familial adenomatous polyposis.<SUP> </SUP><P>

<STRONG>Genetic Testing in Classic or Attenuated Familial Adenomatous Polyposis</STRONG><P>

The most commonly used genetic test detects germ-line alterations<SUP> </SUP>in the <I>APC</I> gene in DNA from peripheral-blood mononuclear cells<SUP> </SUP>by directly sequencing all 15 <I>APC</I> exons. An alternative is the<SUP> </SUP>protein-truncation test.<A HREF="#R27"><SUP>27</SUP></A> In this test, the gene is transcribed<SUP> </SUP>into RNA in vitro and translated into protein, and then the<SUP> </SUP>protein products are electrophoretically separated according<SUP> </SUP>to size. If there is a premature stop codon, a truncated protein<SUP> </SUP>product is generated. The protein-truncation test can miss mutations<SUP> </SUP>that may be deleterious but do not result in the production<SUP> </SUP>of a truncated protein.<SUP> </SUP><P>

The diagnosis of attenuated familial adenomatous polyposis can<SUP> </SUP>be made on the basis of either clinical or genetic criteria.<SUP> </SUP>When the family history, clinical features, and pathological<SUP> </SUP>findings are classic, as in this case, the diagnosis is straightforward.<SUP> </SUP>However, for equivocal cases, genetic testing is a powerful<SUP> </SUP>tool that can provide a definitive diagnosis. In this case,<SUP> </SUP>the role of genetic testing is not to establish the diagnosis,<SUP> </SUP>but to assess the risk of colon cancer in family members whose<SUP> </SUP>carrier status is unknown. Without genetic testing, this patient<SUP> </SUP>is committed to a lifetime of endoscopic surveillance. Consequently,<SUP> </SUP>genetic testing is now considered to be the standard of care<SUP> </SUP>in the management of familial adenomatous polyposis and attenuated<SUP> </SUP>familial adenomatous polyposis.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Genetic Testing and Results</STRONG></FONT><P>

<I>Ms. Kristen M. Shannon</I>: For all inherited cancer syndromes,<SUP> </SUP>the optimal approach is to test an affected family member (the<SUP> </SUP>proband) first. If a mutation is identified, then an asymptomatic<SUP> </SUP>relative can undergo testing, and the results of such testing<SUP> </SUP>will be nearly 100 percent accurate for defining risk. In less<SUP> </SUP>than 20 percent of cases with clinical features of familial<SUP> </SUP>adenomatous polyposis, no mutation is identified in the proband;<SUP> </SUP>this result is uninformative. Potential explanations for an<SUP> </SUP>uninformative test result include mutations that are located<SUP> </SUP>in regions that are not sequenced (such as introns or the promoter)<SUP> </SUP>or involvement of yet-unidentified genes. If an uninformative<SUP> </SUP>test result is obtained, no further testing should be performed<SUP> </SUP>in any family member. Although the failure to identify an <I>APC</I><SUP> </SUP>mutation in the proband does not mean that the diagnosis of<SUP> </SUP>familial adenomatous polyposis or attenuated familial adenomatous<SUP> </SUP>polyposis has been ruled out, it does mean that genetic testing<SUP> </SUP>for the kindred is not an option, and all family members will<SUP> </SUP>require intensive surveillance for cancer.<SUP> </SUP><P>

In families in which no affected relative is available for testing,<SUP> </SUP>consideration can be given to the direct testing of a family<SUP> </SUP>member who is at risk for carrying a mutation. The limitation<SUP> </SUP>of this approach is that the failure to identify a mutation<SUP> </SUP>cannot be interpreted as a true negative in the absence of a<SUP> </SUP>known mutation in the family. Given the nuances of genetic testing,<SUP> </SUP>it is imperative that the ordering practitioner be fully versed<SUP> </SUP>in the indications for testing and in the interpretation of<SUP> </SUP>test results. A retrospective analysis indicated that only 68<SUP> </SUP>percent of the physicians who ordered an <I>APC</I> gene test interpreted<SUP> </SUP>the results correctly.<A HREF="#R28"><SUP>28</SUP></A><SUP> </SUP><P>

The benefits of genetic testing include the elimination of uncertainty<SUP> </SUP>and the provision of an accurate assessment of the risk of cancer<SUP> </SUP>among both carriers and noncarriers of mutations. This approach<SUP> </SUP>is cost effective, particularly when it is initiated at an early<SUP> </SUP>age.<A HREF="#R29"><SUP>29</SUP></A> These benefits must be weighed against the potential<SUP> </SUP>risks. Emotional distress can occur in those found to carry<SUP> </SUP>a mutation as well as in those who are found not to carry a<SUP> </SUP>mutation &#151; so-called survivor guilt. Another perceived<SUP> </SUP>risk is that of genetic discrimination. In this country, however,<SUP> </SUP>there do not appear to be any well-documented cases of discrimination<SUP> </SUP>based on the results of genetic testing for inherited cancer<SUP> </SUP>syndromes.<A HREF="#R30"><SUP>30</SUP></A><SUP>,</SUP><A HREF="#R31"><SUP>31</SUP></A> In addition, 44 states have enacted legislation<SUP> </SUP>to protect people against discrimination by employers or health<SUP> </SUP>insurers on the basis of the results of genetic testing.<SUP> </SUP><P>

Genetic counseling is an essential component of the genetic-testing<SUP> </SUP>process. A counseling session includes discussions of the patterns<SUP> </SUP>of inheritance, the logistics of the genetic test, the possible<SUP> </SUP>test results, the pros and cons of testing, informed consent,<SUP> </SUP>and emotional support. We explore the effects of the diagnosis<SUP> </SUP>on both the patient and the entire family. More than 90 percent<SUP> </SUP>of the patients who have undergone such counseling and testing<SUP> </SUP>for other inherited cancer syndromes have been satisfied with<SUP> </SUP>their decision to do so.<A HREF="#R32"><SUP>32</SUP></A><SUP>,</SUP><A HREF="#R33"><SUP>33</SUP></A> A genetic-counseling session could<SUP> </SUP>also help patients with familial adenomatous polyposis to assess<SUP> </SUP>the desirability of the use of two controversial applications:<SUP> </SUP>prenatal testing and preimplantation diagnosis.<A HREF="#R34"><SUP>34</SUP></A><SUP> </SUP><P>

The patient's father received genetic counseling and underwent<SUP> </SUP><I>APC</I> gene testing with the protein-truncation test. He had a<SUP> </SUP>germ-line mutation that resulted in a premature truncation at<SUP> </SUP>the 5' end of the gene. Subsequent sequencing pinpointed the<SUP> </SUP>truncating mutation to codon 169, confirming the diagnosis of<SUP> </SUP>attenuated familial adenomatous polyposis. The patient herself<SUP> </SUP>subsequently underwent testing. Because a mutation had been<SUP> </SUP>identified in her father, she did not require analysis of the<SUP> </SUP>entire <I>APC</I> gene, and the mutational analysis was limited to<SUP> </SUP>codon 169. She did not carry the truncating mutation, which<SUP> </SUP>indicates that she does not have attenuated familial adenomatous<SUP> </SUP>polyposis.<SUP> </SUP><P>

Neither the patient nor her children will require aggressive<SUP> </SUP>surveillance for cancer. Genetic testing can be recommended<SUP> </SUP>to the patient's older sister (family member III-2), as well<SUP> </SUP>as to her brother's children (IV-1, IV-2, and IV-3). It is not<SUP> </SUP>necessary to test the patient's brother, since he is by definition<SUP> </SUP>a carrier of the gene.<SUP> </SUP><P>

<I>Dr. Kurt J. Isselbacher</I> (Internal Medicine): Do you think we<SUP> </SUP>will soon be able to establish a molecular diagnosis for the<SUP> </SUP>varieties of colon cancer, rather than a pathologically or clinically<SUP> </SUP>descriptive one?<SUP> </SUP><P>

<I>Dr. Chung</I>: Colon cancer is much more heterogeneous on a genetic<SUP> </SUP>level than it is histologically. Three major genetic pathways<SUP> </SUP>that lead to colon cancer are currently recognized: chromosomal<SUP> </SUP>instability, microsatellite instability, and hypermethylation.<SUP> </SUP>Within each of these pathways, there are further subdivisions<SUP> </SUP>with respect to the specific genes that are altered. It will<SUP> </SUP>become possible to identify such a molecular signature for individual<SUP> </SUP>tumors, which will undoubtedly have important prognostic and<SUP> </SUP>therapeutic implications.<SUP> </SUP><P>

<I>Dr. Nancy Lee Harris</I> (Pathology): If the two-hit mechanism of<SUP> </SUP>carcinogenesis requires a second <I>APC</I> mutation in every polyp,<SUP> </SUP>this phenomenon must occur thousands of times in every patient<SUP> </SUP>with familial adenomatous polyposis. Does the <I>APC</I> gene undergo<SUP> </SUP>mutations that frequently in normal persons with no apparent<SUP> </SUP>effect, or does the germ-line mutation somehow increase the<SUP> </SUP>likelihood of a mutation in the other allele?<SUP> </SUP><P>

<I>Dr. Chung</I>: Loss of heterozygosity of the <I>APC</I> gene occurs in<SUP> </SUP>many polyps in patients with familial adenomatous polyposis,<SUP> </SUP>but not in all such polyps. Interestingly, certain <I>APC</I> germ-line<SUP> </SUP>mutations are associated with a loss of heterozygosity, whereas<SUP> </SUP>other <I>APC</I> germ-line mutations are associated with small insertions,<SUP> </SUP>deletions, or point mutations in the second <I>APC</I> allele. This<SUP> </SUP>variability is consistent with the evolving notion that the<SUP> </SUP>nature of the first hit directly influences the type of the<SUP> </SUP>second hit. The mechanism for this phenomenon remains to be<SUP> </SUP>defined, but in familial adenomatous polyposis, it may revolve<SUP> </SUP>around a newly recognized role for the <I>APC</I> gene in the regulation<SUP> </SUP>of chromosomal stability.<SUP> </SUP><P>

<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Final Diagnosis</STRONG></FONT><P>

Attenuated familial adenomatous polyposis syndrome with a germ-line<SUP> </SUP>truncating mutation of the <I>APC</I> gene at codon 169. The patient<SUP> </SUP>does not have the mutation.<SUP> </SUP><P>

<SUP> </SUP><P>

<SUP> </SUP><P>


<FONT SIZE=-1></FONT>
<FONT SIZE=-1></FONT>
<BR><FONT SIZE=+1 FACE="arial, helvetica"><STRONG>Source Information</STRONG></FONT><P><FONT SIZE=-1>
From the Gastrointestinal Unit, Department of Medicine (D.C.C.), the Department of Pathology (M.M.), and the Center for Cancer Risk Analysis (D.C.C., K.M.S.), Massachusetts General Hospital; and the Departments of Medicine (D.C.C.) and Pathology (M.M.), Harvard Medical School.
</FONT><P>


<FONT SIZE=+1 FACE="arial, helvetica"><STRONG>References</STRONG></FONT><P>

<OL COMPACT>
<A NAME="R1"><!-- null --></A>
<LI VALUE=1> Cooper HS. Benign epithelial polyps of the intestines. In: Ming S-C, Goldmen H, eds. Pathology of the gastrointestinal tract. 2nd ed. Baltimore: Williams &amp; Wilkins, 1998:819-53.<!-- HIGHWIRE ID="349:18:1750:1" --><!-- /HIGHWIRE --><A NAME="R2"><!-- null --></A>
<LI VALUE=2>  Rustgi AK. Hereditary gastrointestinal polyposis and nonpolyposis syndromes. N Engl J Med 1994;331:1694-1702.<!-- HIGHWIRE ID="349:18:1750:2" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=nejm&resid=331/25/1694"><nobr>[Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R3"><!-- null --></A>
<LI VALUE=3>  Lynch HT, Smyrk TC, Lanspa SJ, et al. Upper gastrointestinal manifestations in families with hereditary flat adenoma syndrome. Cancer 1993;71:2709-2714.<!-- HIGHWIRE ID="349:18:1750:3" --><A HREF="/cgi/external_ref?access_num=A1993KY91800003&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=8385563&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R4"><!-- null --></A>
<LI VALUE=4>  Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP): a phenotypically and genotypically distinctive variant of FAP. Cancer 1995;76:2427-2433.<!-- HIGHWIRE ID="349:18:1750:4" --><A HREF="/cgi/external_ref?access_num=A1995TJ10600004&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=8625067&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R5"><!-- null --></A>
<LI VALUE=5>  Matsumoto T, Iida M, Kobori Y, et al. Serrated adenoma in familial adenomatous polyposis: relation to germline APC gene mutation. Gut 2002;50:402-404.<!-- HIGHWIRE ID="349:18:1750:5" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=gutjnl&resid=50/3/402"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R6"><!-- null --></A>
<LI VALUE=6>  Williams AR, Balasooriya BAW, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982;23:835-842.<!-- HIGHWIRE ID="349:18:1750:6" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=gutjnl&resid=23/10/835">[Abstract]</A><!-- /HIGHWIRE --><A NAME="R7"><!-- null --></A>
<LI VALUE=7>  Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001;96:2992-3003.<!-- HIGHWIRE ID="349:18:1750:7" --><A HREF="/cgi/external_ref?access_num=10.1016/S0002-9270(01)03239-7&link_type=DOI">[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000171445900033&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=11693338&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R8"><!-- null --></A>
<LI VALUE=8>  Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-932.<!-- HIGHWIRE ID="349:18:1750:8" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=nejm&resid=348/10/919"><nobr>[Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R9"><!-- null --></A>
<LI VALUE=9>  Lynch HT, Smyrk TC, Lanspa SJ, et al. Phenotypic variation in colorectal adenoma/cancer expression in two families: hereditary flat adenoma syndrome. Cancer 1990;66:909-915.<!-- HIGHWIRE ID="349:18:1750:9" --><A HREF="/cgi/external_ref?access_num=A1990DX69600015&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=2386918&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R10"><!-- null --></A>
<LI VALUE=10>  Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 2002;45:127-136.<!-- HIGHWIRE ID="349:18:1750:10" --><A HREF="/cgi/external_ref?access_num=000173329600025&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=11786778&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R11"><!-- null --></A>
<LI VALUE=11>  Laurent-Puig P, Beroud C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 1998;26:269-270.<!-- HIGHWIRE ID="349:18:1750:11" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=nar&resid=26/1/269"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R12"><!-- null --></A>
<LI VALUE=12>  Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79-83.<!-- HIGHWIRE ID="349:18:1750:12" --><A HREF="/cgi/external_ref?access_num=A1997XU72400022&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=9288102&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R13"><!-- null --></A>
<LI VALUE=13>  Dihlmann S, Gebert J, Siermann A, Herfarth C, von Knebel Doeberitz M. Dominant negative effect of the APC1309 mutation: a possible explanation for genotype-phenotype correlations in familial adenomatous polyposis. Cancer Res 1999;59:1857-1860.<!-- HIGHWIRE ID="349:18:1750:13" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=canres&resid=59/8/1857"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R14"><!-- null --></A>
<LI VALUE=14>  Heppner Goss K, Trzepacz C, Tuohy TMF, Groden J. Attenuated APC alleles produce functional protein from internal translation initiation. Proc Natl Acad Sci U S A 2002;99:8161-8166.<!-- HIGHWIRE ID="349:18:1750:14" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=99/12/8161"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R15"><!-- null --></A>
<LI VALUE=15>  Spirio L, Samowitz W, Robertson J, et al. Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet 1998;20:385-388.<!-- HIGHWIRE ID="349:18:1750:15" --><A HREF="/cgi/external_ref?access_num=10.1038/3865&link_type=DOI">[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000077199600029&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=9843214&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R16"><!-- null --></A>
<LI VALUE=16>  Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003;138:560-570.<!-- HIGHWIRE ID="349:18:1750:16" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=annintmed&resid=138/7/560"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R17"><!-- null --></A>
<LI VALUE=17>  Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348:791-799.<!-- HIGHWIRE ID="349:18:1750:17" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=nejm&resid=348/9/791"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R18"><!-- null --></A>
<LI VALUE=18>  Lynch HT, Watson P. AFAP: variety is the spice of life. Gut 1998;43:451-452.<!-- HIGHWIRE ID="349:18:1750:18" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=gutjnl&resid=43/4/451"><nobr>[Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R19"><!-- null --></A>
<LI VALUE=19>  Zwick A, Munir M, Ryan CK, et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997;113:659-663.<!-- HIGHWIRE ID="349:18:1750:19" --><A HREF="/cgi/external_ref?access_num=A1997XQ41000049&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=9247488&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R20"><!-- null --></A>
<LI VALUE=20>  Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188.<!-- HIGHWIRE ID="349:18:1750:20" --><A HREF="/cgi/external_ref?access_num=A1994PJ58600034&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=7926468&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R21"><!-- null --></A>
<LI VALUE=21>  Yang VW, Shields JM, Hamilton SR, et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998;58:1750-1753.<!-- HIGHWIRE ID="349:18:1750:21" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=canres&resid=58/8/1750">[Abstract]</A><!-- /HIGHWIRE --><A NAME="R22"><!-- null --></A>
<LI VALUE=22>  Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.<!-- HIGHWIRE ID="349:18:1750:22" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=nejm&resid=328/18/1313"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R23"><!-- null --></A>
<LI VALUE=23>  Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.<!-- HIGHWIRE ID="349:18:1750:23" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=nejm&resid=342/26/1946"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R24"><!-- null --></A>
<LI VALUE=24>  Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122:641-645.<!-- HIGHWIRE ID="349:18:1750:24" --><A HREF="/cgi/external_ref?access_num=000174056900009&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=11874996&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R25"><!-- null --></A>
<LI VALUE=25>  Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-1059.<!-- HIGHWIRE ID="349:18:1750:25" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=nejm&resid=346/14/1054"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R26"><!-- null --></A>
<LI VALUE=26>  Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-860.<!-- HIGHWIRE ID="349:18:1750:26" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=gutjnl&resid=50/6/857"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R27"><!-- null --></A>
<LI VALUE=27>  Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993;329:1982-1987.<!-- HIGHWIRE ID="349:18:1750:27" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=nejm&resid=329/27/1982"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R28"><!-- null --></A>
<LI VALUE=28>  Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997;336:823-827.<!-- HIGHWIRE ID="349:18:1750:28" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=nejm&resid=336/12/823"><nobr>[Abstract/Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R29"><!-- null --></A>
<LI VALUE=29>  Cromwell DM, Moore RD, Brensinger JD, Petersen GM, Bass EB, Giardiello FM. Cost analysis of alternative approaches to colorectal screening in familial adenomatous polyposis. Gastroenterology 1998;114:893-901.<!-- HIGHWIRE ID="349:18:1750:29" --><A HREF="/cgi/external_ref?access_num=000073256500009&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=9558276&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R30"><!-- null --></A>
<LI VALUE=30>  Stephenson J. Genetic test information fears unfounded. JAMA 1999;282:2197-2198.<!-- HIGHWIRE ID="349:18:1750:30" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=jama&resid=282/23/2197"><nobr>[Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R31"><!-- null --></A>
<LI VALUE=31>  Nowlan W. Human genetics: a rational view of insurance and genetic discrimination. Science 2002;297:195-196.<!-- HIGHWIRE ID="349:18:1750:31" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=sci&resid=297/5579/195"><nobr>[Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE --><A NAME="R32"><!-- null --></A>
<LI VALUE=32>  Aktan-Collan K, Mecklin JP, Jarvinen H, et al. Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer 2000;89:44-50.<!-- HIGHWIRE ID="349:18:1750:32" --><A HREF="/cgi/external_ref?access_num=10.1002/(SICI)1097-0215(20000120)89:1<44::AID-IJC8>3.0.CO;2-3&link_type=DOI">[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000085169400008&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=10719730&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R33"><!-- null --></A>
<LI VALUE=33>  Esplen MJ, Madlensky L, Butler K, et al. Motivations and psychosocial impact of genetic testing for HNPCC. Am J Med Genet 2001;103:9-15.<!-- HIGHWIRE ID="349:18:1750:33" --><A HREF="/cgi/external_ref?access_num=10.1002/ajmg.1493.abs&link_type=DOI">[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000170711000002&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=11562928&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --><A NAME="R34"><!-- null --></A>
<LI VALUE=34>  Ao A, Wells D, Handyside AH, Winston RM, Delhanty JD. Preimplantation genetic diagnosis of inherited cancer: familial adenomatous polyposis coli. J Assist Reprod Genet 1998;15:140-144.<!-- HIGHWIRE ID="349:18:1750:34" --><A HREF="/cgi/external_ref?access_num=10.1023/A:1023008921386&link_type=DOI">[CrossRef]</A><A HREF="/cgi/external_ref?access_num=000072678300006&link_type=ISI" onClick="ISIwin('ISI')" TARGET="ISI">[ISI]</A><A HREF="/cgi/external_ref?access_num=9547690&link_type=MED" onClick="ISIwin('ISI')" TARGET="ISI">[Medline]</A><!-- /HIGHWIRE --></OL>






		
        
        
	
	
	
	
	






 




<BR CLEAR=ALL>


	
	 
		  
			 
			
			                    



 
	 

<table border="0" cellpadding="0" cellspacing="0" width="200" ALIGN="RIGHT">
<tr>
<td width="20">&nbsp;</td>
<TD BGCOLOR="336699">

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="1">

	<TR VALIGN="top">
		<td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
			<img src="/icons/v3_this_article.gif" alt="This Article" width="73" height="8" BORDER="0"><BR>
			<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
	</tr><tr>
		<td> 
                <table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
		<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
		
		
		
		

		
		 

		
		<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b>
			
			
			
				
						
						<A class="contentboxLinks" HREF="/cgi/reprint/349/18/1750.pdf">PDF</A></b></font></td></tr>
		
		<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/ac_external_ref?link_type=pda_mms&doi=10.1056%2FNEJMcpc030023">PDA Full Text</A></b></font></td></tr>
		
		
		

		

		

		 
		
		



	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	</table>
        </td>
        </tr>









	<tr> 
	<td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
	<img src="/icons/v3_tools_service.gif" alt="Tools and Services" width="103" height="9" align="absmiddle"><BR>
	<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
	</tr>
	<tr> 
	<td> 
	<table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	
		
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/folders?action=addtofolder&wherefrom=JOURNALS&wrapped_id=nejm;349/18/1750">Add to Personal Archive</A></b></font></td></tr>
	
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/citmgr?gca=nejm;349/18/1750">Add to Citation Manager</A></b></font></td></tr>
	
	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/mailafriend?url=http://content.nejm.org/cgi/content/short/349/18/1750&title=Case+34-2003+-+A+45-Year-Old+Woman+with+a+Family+History+of+Colonic+Polyps+and+Cancer"><b>Notify a Friend</b></a></b></font></td></tr>

	
        <tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=nejm;349/18/1750&return_type=article&return_url=%2Fcgi%2Fcontent%2Ffull%2F349%2F18%2F1750">E-mail When Cited</A></b></font></td></tr>

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/ac_external_ref?link_type=letters_mms&doi=10.1056%2FNEJMcpc030023">E-mail When Letters Appear</A></b></font></td></tr>
	
	
	
	

	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
	</table>
        </td>
        </tr>



        <tr>
        <td width="200" bgcolor="#E8E8D1" ALIGN="CENTER"><img src="/icons/home/spacer.gif" width="1" height="6" alt=""><BR>
	<img src="/icons/v3_more_information.gif" alt="More Information" width="116" height="8" align="absmiddle"><BR>
	<img src="/icons/home/spacer.gif" width="1" height="6" alt=""></td>
        </tr>
        <tr>
        <td>
        <table cellpadding="2" cellspacing="0" width="100%" BORDER="0" BGCOLOR="#FFFFFF">
	<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
        

	

	

	

	

	

	

	

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/search?qbe=nejm;349/18/1750&journalcode=nejm&minscore=5000">Find Similar Articles</A></b></font></td></tr>

	
	<tr valign="top"><td WIDTH=15 valign="top" ALIGN="CENTER"><img src="/icons/v3_arrow_right.gif" alt="-" border="0" width="9" height="8" vspace="3"></td><td valign="middle"><font face="arial, helvetica, sans-serif" size=-1><b><A class="contentboxLinks" HREF="/cgi/external_ref?access_num=14585944&link_type=PUBMED" onClick="ISIwin('ISI')" TARGET="ISI">PubMed Citation</A></b></font></td></tr>

<tr valign="top"><td colspan="2"><img src="/icons/home/spacer.gif" alt="" height="1" border="0" hspace="3"></td></tr>
</table>
</td>
</tr>

        
        
</table>
</table>	 <!-- end of outer content box1 -->
</TABLE>	 <!-- end of outer content box2 -->



			
			
					
	









<BR CLEAR=ALL>


	

	<table width="100%" border="0" cellspacing="0" cellpadding="0" align="center">
	<tr> 
	<td align="center"><hr size="1" color="#000000" noshade>
	<p><font face="arial, helvetica, sans-serif">
	<a href="/" class="footerLinks">HOME</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/search.dtl" class="footerLinks">SEARCH</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/current.shtml" class="footerLinks">CURRENT ISSUE</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/contents-by-date.0.shtml" class="footerLinks">PAST ISSUES</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/collections/" class="footerLinks">COLLECTIONS</a> &nbsp;&nbsp;|&nbsp;&nbsp;
	<a href="/help/" class="footerLinks">HELP</a>
</font></p>
	<p><font face="arial, helvetica, sans-serif">Comments and questions?
	Please <a href="http://www.nejm.org/custserv/feedback.asp">contact us</a>.</font></p>
	<p><font face="Times New Roman">
	<font face="Times New Roman"><b>The New England Journal of Medicine is owned, published, and <a href="http://www.nejm.org/aboutnejm/copyright.asp">copyrighted</a> &copy; 2005 <A HREF ="http://www.massmed.org/">Massachusetts Medical Society</A>.
	All rights reserved.</b></font>
</font></p></td>
	</tr>
	</table>



        <SCRIPT LANGUAGE="JavaScript">
        <!--
        function startTarget(windowname,wid,hei) {
        
        var dotpos = windowname.indexOf(".");
        if (dotpos > -1)
        {
        var tempwn = windowname.substring(0,dotpos) +
                windowname.substring(dotpos + 1, windowname.length);
        windowname = tempwn;
        }
        var sizestring = 'width=' + wid + ',height=' + hei;
        window.open('',windowname,'scrollbars,resizable,menubar,' + sizestring + '\'');
        }
        // -->
        </SCRIPT>

<script language="JavaScript">
<!--
if ( top != self )
{
     top.location.href = unescape(window.location.pathname);
}

function ISIwin(windowname) {
	var dotpos = windowname.indexOf(".");
	if (dotpos > -1) {
		var tempwn = windowname.substring(0,dotpos) +
        windowname.substring(dotpos + 1, windowname.length);
		windowname = tempwn;
	}
	newwin = window.open('', windowname, 'width=700,height=400,left=30,top=30,screenX=30,screenY=30,resizable,scrollbars,toolbar,location,status,menubar');
	setTimeout('newwin.focus();',250);
}

//-->
</script>

</BODY>
</HTML>

